anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: To examine the prevalence of menstrual pain among women of reproductive age and its impact on their daily lives and professional responsibilities.
METHODS: A cross-sectional and descriptive study was conducted in July and August 2022. Phone interviews were carried out using a random system to select women aged between 15 and 49 years old. The questionnaire included sociodemographic variables, contraception method used, characteristics of the menstrual pattern (pain and bleeding amount), its influence on their working life, and if they would need to resort to sick leaves due to the impairments arising from the menstrual symptoms.
RESULTS: A total of 1800 women representative of the Spanish population took part in this study. 72.6% of them report menstrual pain, with 45.9% requiring medication. 35.9% identify their menstrual bleeding as intense or very intense. 38.8% assert that menstrual discomforts affect their everyday life. 34.3% would have required not attending their work activities or having requested sick leave due to the discomforts, although only 17.3% of the women finally requested so, mainly because 58.4% considered that it might imply consequences in their professional environment, especially those with Higher Education. The women who report more discomfort are the youngest ones and those who resort to condoms as a contraceptive method (p < 0.001).
CONCLUSIONS: Menstrual pain is a prevalent problem among women of reproductive age and can affect their everyday life and professional environment, requiring work leaves on some occasions.
UNLABELLED: Brain fog is an undefined term describing a cluster of symptoms related to fatigue and impaired memory, attention, and concentration. Brain fog or brain fog-like symptoms have been reported in central disorders of hypersomnolence and in a range of seemingly unrelated disorders, including coronavirus disease 2019, major depressive disorder, multiple sclerosis, lupus, and celiac disease. This narrative review summarizes current evidence and proposes a consensus definition for brain fog. Brain fog is prevalent in narcolepsy and idiopathic hypersomnia, with more than three-quarters of patients with either disorder reporting this symptom in a registry study; it has also been reported as particularly difficult to treat in idiopathic hypersomnia. Studies directly evaluating brain fog are rare; tools for evaluating this symptom cluster typically are patient reports, with few objective measures validated in any disorder. Evaluating brain fog is further complicated by confounding symptoms, such as excessive daytime sleepiness, which is a hallmark of hypersomnolence disorders. No treatments specifically address brain fog. The paucity of literature, assessment tools, and medications for brain fog highlights the need for research leading to better disambiguation and treatment. Until a clear consensus definition is established, we propose brain fog in hypersomnia disorders be defined as a cognitive dysfunction that may or may not be linked with excessive sleepiness, related to an underlying neuronal dysfunction, which reduces concentration and impairs information processing, leading to a complaint of lack of clarity of mental thinking and awareness.
CITATION: Rosenberg R, Thorpy MJ, Doghramji K, Morse AM. Brain fog in central disorders of hypersomnolence: a review. J Clin Sleep Med. 2024;20(4):643-651.
In addition to resistance exercises, NMES will be applied to the quadriceps muscles in both legs of the patients in this group. The application will be made with a portable device using disposable electrodes. One of the electrodes will be placed proximally, that is, at the midpoint of the quadriceps muscle, while the second electrode will be placed on the distal part. In order to ensure that the patients get used to the device, low-intensity current with a frequency range of 5 Hz, 10-30 minutes. Afterward, the treatment program will continue with a high-frequency current with a frequency range of 50 Hz, 15 minutes. Participants were instructed to voluntarily contract the quadriceps muscles during periods of HF-NMES stimulation to increase the strengthening effect and improve NMES tolerance.
Implementing Advance Care Planning (ACP) for patients with End-Stage Kidney Disease (ESKD), particularly in the context of hemodialysis, presents significant challenges. Despite existing legal frameworks, disparities in advance care planning practices are evident across Europe. The present perspective introduces a multidisciplinary model, initiated in 2019. This model incorporates a specialized team comprising a nephrologist, a psychologist, a palliative care specialist, and an anesthesiologist/intensivist. Through this collaborative approach, we aimed to comprehensively address the intricate medical, emotional, and psychological dimensions in advance care planning. In this point of view, we discuss the strengths of our model, its potential for European Nephrology, and advocate for guidelines to enhance advance care planning implementation within the nephrology community.
Prostaglandin E2 (PGE2) is an important lipid molecule derived from arachidonic acid, which regulates a variety of physiological and pathological activities. Based on the inhibition of inflammatory PGE2 production, non-steroidal anti-inflammatory drugs (NSAIDs) are considered as the most commonly used drugs to treat inflammatory diseases and to relieve fever and pain symptoms. PGE2 mediates its functions via four different G protein-coupled receptors, named EP1-EP4. Though the limited distribution and low PGE2 affinity of EP1, it plays important roles in the maintenance of many physiological functions and homeostasis. Moreover, EP1 is widely involved in the inflammatory response, pain perception and multisystem pathological function regulation. In this review, we will briefly summarize the recent advances on the physiological and pathophysiological function of EP1 and its targeted drugs development.
The safety and efficacy of epoetin alfa were evaluated in 4 placebo-controlled studies enrolling 297 anemic patients (hemoglobin < 10 g/dL) with HIV infection receiving concomitant therapy with zidovudine. In the subgroup of patients (89/125 epoetin alfa and 88/130 placebo) with pre-study endogenous serum erythropoietin levels ≤ 500 mUnits/mL, epoetin alfa reduced the mean cumulative number of units of blood transfused per patient by approximately 40% as compared to the placebo group. Among those patients who required RBC transfusions at baseline, 43% of patients treated with epoetin alfa versus 18% of placebo-treated patients were RBC transfusion-independent during the second and third months of therapy. Epoetin alfa therapy also resulted in significant increases in hemoglobin in comparison to placebo. When examining the results according to the weekly dose of zidovudine received during month 3 of therapy, there was a statistically significant reduction (p < 0.003) in RBC transfusion requirements in patients treated with epoetin alfa (n = 51) compared to placebo-treated patients (n = 54) whose mean weekly zidovudine dose was ≤ 4200 mg/week.

Approximately 17% of the patients with endogenous serum erythropoietin levels ≤ 500 mUnits/mL receiving epoetin alfa in doses from 100 to 200 Units/kg 3 times weekly achieved a hemoglobin of 12.7 g/dL without administration of RBC transfusions or significant reduction in zidovudine dose. In the subgroup of patients whose pre-study endogenous serum erythropoietin levels were > 500 mUnits/mL, epoetin alfa therapy did not reduce RBC transfusion requirements or increase hemoglobin compared to the corresponding responses in placebo-treated patients.
This randomized clinical trial will be conducted at Riphah Rehab center over duration of eight months. The sample size will consist of 58 participants. Participants which meet the inclusion criteria will be taken through non-probability convenience sampling technique. 29 Participants will be assigned to Group A 29 to group B. Data will be collected using various assessment tools, including NPRS, ULFI, Universal Goniometer, Hand Held Dynamometer. Pre-intervention assessments will be conducted for groups. Data analysis will be performed by using SPSS 26 software.
The invention discloses a Chinese patent drug for treating toothache, which contains the following material medicines by weight proportions: 3-10 portions of beam root, 25-35 portions of gypsum, 5-15 portions of corn mint, and 5-15 portions of lesser galangal. During production, the gypsum is grinded into powder, then the beam root, the corn mint, and the lesser galangal are mixed and grinded into powder, and then the powders are mixed evenly for making pulvis, then the pulvis is enclosed into a filter paper bag. The medicament disclosed by the invention is lesser but better, can treat the symptoms and root of the disease simultaneously, is applicable for the sufferers with gingivitis, pulpitis, parodontitis, pericoronitis, tip pericoronitis, and other dental disease. The cure rate reaches 93.2 percent, and the total effectivity reaches 98.4 percent. The medicine directly acts on the afflicted part of toothache by external rinse in mouth, the cure on common sufferer can take effect exactly on the same day, the sufferer can be healed within two weeks, dispensing with hospitalization. The usage of the medicine is safer without harmful side effect. So that the patient suffers less pain, with less cost, and can accept the Chinese patent drug easier.
To select the core target (RAB13) in sepsis patients' peripheral blood and investigate its molecular functions and possible mechanisms. The peripheral blood of sepsis patients (n = 21) and healthy individuals (n = 9) within 24 h after admission were collected for RNA-seq, and differential gene screening was performed by iDEP online analysis software (P < 0.01; log2FC ≥ 2) and enrichment analysis, the potential core target RAB13 was screened out. The association between RAB13 expression and sepsis severity was explored using multiple datasets in the GEO database, and survival analysis was conducted. Subsequently, peripheral blood mononuclear cells (PBMCs) from sepsis and control groups were isolated, and 10 × single-cell sequencing was used to identify the main RAB13-expressing cell types. Finally, LPS was used to stimulate THP1 cells to construct a sepsis model to explore the function and possible mechanism of RAB13. We found that RAB13 was a potential core target, and RAB13 expression level was positively associated with sepsis severity and negatively correlated with survival based on multiple public datasets. A single-cell sequencing indicated that RAB13 is predominantly localized in monocytes. Cell experiments validated that RAB13 is highly expressed in sepsis, and the knockdown of RAB13 promotes the polarization of macrophages towards the M2 phenotype. This mechanism may be associated with the ECM-receptor interaction signaling pathway. The upregulation of RAB13 in sepsis patients promotes the polarization of M2-like macrophages and correlates positively with the severity of sepsis.
OBJECTIVES: There is a scarcity of data regarding the effects of kinesiophobia on stroke patients with hemiplegia. Therefore, this paper aims to evaluate the level of kinesiophobia experienced by stroke patients with hemiplegia in China, examine the elements that influence it, and investigate the unique psychological experience of kinesiophobia combined with a qualitative study.
METHODS: This mixed study was conducted in two steps. Four approved scales were used to evaluate a total of 163 patients: (i) Tampa Scale of Kinesiophobia, (ii) Pain Catastrophizing Scale, (iii) Self-Efficacy for Exercise Scale, and (iv) Hospital Anxiety and Depression Scale. A multivariate linear regression model was used to evaluate the predictors of kinesiophobia in stroke patients with hemiplegia. Subsequently, semi-structured interviews with 15 stroke patients with hemiplegia were conducted using an objective sampling method, and the Colaizzi 7-step analysis process was utilized to analyze the interview data.
RESULTS: A total of 163 stroke patients with hemiplegia were included in this study, of them, 47.9% reported kinesiophobia. Multiple linear regression revealed that the influencing factors of kinesiophobia in stroke patients with hemiplegia were a history of falls, exaggeration, helplessness, anxiety, depression, and low exercise self-efficacy (P<0.05). The qualitative research focuses on two main topics: personal adoption of negative coping styles and insufficient external support.
CONCLUSION: Our study showed that the kinesiophobia in stroke patients with hemiplegia was high, with several factors influencing their kinesiophobia. Some of these factors are modifiable and should be considered when formulating kinesiophobia intervention strategies for stroke patients with hemiplegia.
Peg Interferon Alpha 2b (Peg Intron) 4.5 micrograms/kg once a week. ARA-C 10 mg under the skin daily.
PROBLEM TO BE SOLVED: To obtain a cosmetic excellent in water resistance and sweet resistance by combining 4-t-butyl-4'-methoxydibenzoylmethane with a specific alkyl-modified carboxylvinyl polymer with a specific diester compound. SOLUTION: This cosmetic is obtained by combining 4-t-butyl-4'- methoxydibenzoylmethane which is an ultraviolet light absorbent with an alkyl- modified carboxyvinyl polymer as a thickener and a diester which is a liquid at 20 deg.C. A coating agent may further be added to the system. A blend amount of the ultraviolet light absorbent is preferably >=0.01wt.% and <=20wt.% based on the cosmetic and e.g. an acrylic acid methacrylic acid alkyl copolymer is preferably used as the thickener and the blend amount is preferably >=0.01wt.% and <=10wt.%. For example, dioleyl oxalate or dimethyl maleate is preferably used as the diester and the blend amount is preferably >=0.05wt.% and <=40wt.%. A polyvinylpyrrolidone-alkyl copolymer is preferably used as the coating agent and preferably blended in an amount of about >=0.5wt.% and <=30wt.%.
The COVID-19 pandemic has caused a substantial strain on the healthcare system, with at least 14% of infected patients requiring hospitalization. Identifying ways to ameliorate the progression and severity of the COVID-19 infection and preventing hospitalization is critical. Patients suffering from COVID-19 have been shown to have a significant inflammatory response resembling that of cytokine release syndrome, and it is this inflammatory phase that is thought to drive fatality.

To this end, a multi-center randomized clinical trial to determine the efficacy of resistant starch in reducing the need for hospitalization for COVID-19 positive patients will be studied. This study will enroll 1500 non-hospitalized COVID-19 positive individuals who are being monitored in the outpatient setting. Patients will be randomized to either a dietary supplement containing resistant starch or a placebo for 14 days. Our primary outcome is the rate of hospitalization for COVID-19 related complications. Secondary outcomes will look at time to recovery and symptom severity scores.
PURPOSE: A topical sunscreen composition is provided to form an anhydrous composition which prevents the tendency to whiten in water by dissolving a solid organic UV sunscreen filter in a composition containing C_2 or C_3 monoalcohol and an oil portion. CONSTITUTION: A topical sunscreen composition contains 10 wt% or more of C_2 or C_3 monoalcohol, a solid organic UV filter, and an oil portion containing one or more oils. The oil portion is miscible with the C_2 or C_3 monoalcohol. The interfacial tension between the oil portion and water is 9-32.5. The volume fraction of the oil portion with respect to the C_2 or C_3 monoalcohol plus the oil portion is about 0.44 or greater. The composition substantially free of a mixture of a low volatility C_2 or C_3 liquid silicone and a branched fatty acid ester of a polyprotic carboxylic acid in a ratio of 3:1-4.25:1.
An agent that positively modulates Î²2-adrenergic receptor conformation, receptor activity or activation thereof for use in the improvement of skin scar colour matching, for example, reducing scar hyperpigmentation. Patients treated are selected as being at risk of hyperpigmentation on the basis of one or more of the following factors; (a) Have previously developed hyperpigmentation of a scar. (b) Tans readily on exposure to sunlight or ultraviolet (UV) radiation rather than burning. (c) Has a non-Caucasian racial origin. (d) Skin colour (i.e., that not tanned) is considered to be darker than that typical of a naturally fair-haired Caucasian. The subject may be selected as being at risk of hyperpigmentation because they are at least predominantly of Chinese, black African, Asian, or Southern European racial origin and/or if their skin type can be assessed under the Fitzpatrick Scale as Type III, IV, V or VI. Compositions comprising and cosmetic methods of treatment using the said agent are also disclosed.
Paper of high wet strength contains cellulose fibres regenerated in situ from xanthated fibres containing 5 to 30% by weight of combined carbon disulphide.  It may be made by mixing the xanthated fibres with paper-making fibres, making the mixture into paper by a wet process and drying at a temperature at which the xanthated cellulose is converted to regenerated cellulose. The paper may also contain manmade fibres, e.g. of regenerated cellulose, polyamide, polyvinyl alcohol or polyester, or a binding agent, e.g. alginate, C.M.C. or polyvinyl alcohol powder. The paper may be permitted to shrink freely as it dries to obtain a rough-surfaced paper, which is absorbent and may be used in cold permanent waving.  Alternatively, it may be creped.
SFX-01 with Fulvestrant SFX-01 when used in combination with fulvestrant. All patients will continue to receive fulvestrant 500 mg IM in 28 day cycles. As patients will already have been taking this, a repeat loading dose is not necessary. Commencing on study D1 patients will take SFX-01, which is provided as 300 mg capsules, one to be taken twice daily, 12 hours apart, after food (preferably within 2 hours).
OBJECTIVE: Multiple sclerosis is a serious neurodegenerative disorder that causes disability in young adults. Genetic predisposition of multiple sclerosis is well documented and several single nucleotide polymorphisms (SNPs) of the CD58 were found to be associated with this disease. This systematic review and meta-analysis were done with the aim of finding the association between CD58 gene SNPs (rs12044852 and rs2300747) and the risk of multiple sclerosis (MS).
METHOD: A comprehensive search was done in PubMed, Google Scholar, Embase, and MSGene.org to find the relevant data. Our search yielded 13 relevant publications which were included for meta-analysis consisting of 5194 cases and 5766 controls. All the statistical analysis was conducted using meta and metafor packages in R studio. The odds ratio (OR) along with 95 % confidence intervals and p values were determined using the fixed effects and random effects model. The I2 test was done to measure heterogeneity. Subgroup analysis was performed along with analysis for publication bias.
RESULTS: We found significant association for both rs12044852 (allelic, dominant, over-dominant, heterozygous, and homozygous models) and rs2300747 (allelic, dominant, over-dominant, heterozygous models) with multiple sclerosis. Both the SNPs provided a protective effect for multiple sclerosis. Subgroup analysis indicated that rs12044852 polymorphism provided a protective effect in both Asians and Caucasians. However, for rs2300747, the Asian population showed no statistically significant association with the risk of MS.
CONCLUSION: Polymorphism of rs12044852 and rs2300747 of the CD58 gene provided a protective effect for multiple sclerosis. The protective effect is more prominent in Caucasian populations compared to Asians.
Imaging will include research PET/MRI of pelvis within 30 days of multiregion tissue collection. Concretely, in patients triaged to primary debulking surgery (PDS), PET/MRI will be obtained within 30 days preceding multi-region tissue collection at the time of PDS (already being done under IRB# 06-107).
Ceftobiprole medocaril is a cephalosporin antibiotic with anti-MRSA (Methicillin-Resistant Staphylococcus Aureus) activity. Ceftobiprole medocaril is not yet approved for the treatment of complicated skin and skin structure infections. This is a randomized, double-blind, multicenter study of ceftobiprole medocaril plus placebo versus a comparator to assess the effectiveness and safety of ceftobiprole medocaril in patients with complicated skin and skin structure infections. The patients will be randomized to ceftobiprole medocaril plus placebo or a comparator. The primary endpoint is the clinical cure rate of ceftobiprole medocaril at the test-of-cure visit. The patients will receive either ceftobiprole medocaril plus placebo or a comparator for 7 to 14 days (unless extended at discretion of medical monitor).
How do we perceive others based on their voices? This question has attracted research and media attention for decades, producing hundreds of studies showing that the voice is socially and biologically relevant, but these studies vary in methodology and ecological validity. Here we test whether vocalizers producing read versus free speech are judged similarly by listeners on ten biological and/or psychosocial traits. In perception experiments using speech from 208 men and women and ratings from 4,088 listeners, we show that listeners' assessments of vocalizer sex and age are highly accurate, regardless of speech type. Assessments of body size, femininity-masculinity and women's health also did not differ between free and read speech. In contrast, read speech elicited higher ratings of attractiveness, dominance and trustworthiness in both sexes and of health in males compared to free speech. Importantly, these differences were small, and we additionally show moderate to strong correlations between ratings of the same vocalizers based on their read and free speech for all ten traits, indicating that voice-based judgments are highly consistent within speakers, whether or not speech is spontaneous. Our results provide evidence that the human voice can communicate various biological and psychosocial traits via both read and free speech, with theoretical and practical implications.
Permitted to receive a red blood cell transfusion if the blood count is below 8 g/dL and the physician believes it is in the patient's best interest. A transfusion will be strongly recommended if the blood count drops to less than 7 g/dL. If the patient has symptoms of angina (e.g., chest discomfort described as pressure or heaviness) that do not go away with medication, a blood transfusion will be ordered regardless of the blood count.
The present invention relates to a novel compound medicine for treating wart, which is an orally taken new medicine for treating flat wart. The present invention adopts reserpine, moroxydine and vitamin A which are prepared into grains or powder according to a certain unitage, and the grains or powder is mixed and prepared into coated tablets. The present invention has the characteristics of low cost, convenience for treatment, conspicuous curative effect, etc. The preparation dosage is reasonable, and compound medicines of various shapes for treating wart can be produced. Compared with the existing medicines for treating flat wart, the medicine has the advantages of low cost, little side effect, no scar after cure, easy acceptance of patients, etc. The present invention accords with the requirement for hygienic standards and is suitable for patients with flat wart to take.